SEARCH:   Advanced

Blood, 15 January 2004, Vol. 103, No. 2, pp. 422-427. Prepublished online as a Blood First Edition Paper on October 2, 2003; DOI 10.1182/blood-2003-01-0069. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-01-0069v1 103/2/422    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith-Whitley, K. Articles by Ohene-Frempong, K. Search for Related Content PubMed PubMed Citation Articles by Smith-Whitley, K. Articles by Ohene-Frempong, K. Related Collections Clinical Trials and Observations Red Cells Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Epidemiology of human parvovirus B19 in children with sickle cell disease Kim Smith-Whitley, Huaqing Zhao, Richard L. Hodinka, Janet Kwiatkowski, Renèe Cecil, Tamara Cecil, Avital Cnaan, and Kwaku Ohene-Frempong From the Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA; Division of Biostatistics and Epidemiology, The Children's Hospital of Philadelphia, Philadelphia, PA; Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, University of Pennsylvania, School of Medicine, Philadelphia. Human parvovirus (HPV) B19 causes significant morbidity and mortality in children with sickle cell disease (SCD), but little data are published about the epidemiology of HPV B19 infection and its associated complications in this patient population. In this study, prevalence and incidence rates of HPV B19 were determined in 633 patients with SCD followed at The Children's Hospital of Philadelphia between November 1996 and December 2001. Thirty percent (30%) were HPV B19 immunoglobulin G (IgG) positive at first testing, and the 70% without evidence of past HPV B19 infection were tested annually. One hundred ten patients developed evidence of HPV B19 infection for an incidence rate of 11.3 per 100 patientyears. Sixty-eight episodes of HPV B19–induced transient red cell aplasia occurred with the following clinical events: fever (89.7%), pain (61.8%), acute splenic sequestration (19.1%), and acute chest syndrome (11.8%). Pain, fever, and acute splenic sequestration were more frequent events with acute HPV B19 infections compared with acute events in uninfected patients. The results of this epidemiologic study, the largest and most comprehensive to date, justify the development of HPV B19 prevention strategies to diminish the frequent and often severe complications associated with HPV B19 infections in patients with SCD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. S. Young and K. E. Brown Parvovirus B19 N. Engl. J. Med., February 5, 2004; 350(6): 586 - 597. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020